Key result
The combination of an antiplatelet drug with a reduced dose of a direct oral anticoagulant is proposed as a rational treatment to prevent both arterial and venous thromboembolism in hyperhomocysteinemia.
Population
Patients with hyperhomocysteinemia (HHcy) and associated thrombophilia
Design
Editorial
Authors
Loading...
The author proposes that combining an antiplatelet drug with a reduced-dose DOAC, alongside vitamin supplementation, may be a rational approach to prevent both arterial and venous thrombosis in patients with hyperhomocysteinemia.
The author proposes that combining an antiplatelet drug with a reduced-dose DOAC, alongside vitamin supplementation, may be a rational approach to prevent both arterial and venous thrombosis in patients with hyperhomocysteinemia.
Federico Cacciapuoti (2020) conducted a letter in Hyperhomocysteinemia. Antiplatelet drug combined with reduced dose DOAC was evaluated. The combination of an antiplatelet drug with a reduced dose of a direct oral anticoagulant is proposed as a rational treatment to prevent both arterial and venous thromboembolism in hyperhomocysteinemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: